NEUPRO 4mg/24h, 6mg/24h, 8mg/24h Transdermal patch (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Neupro 4 mg/24 h transdermal patch. Neupro 6 mg/24 h transdermal patch. Neupro 8 mg/24 h transdermal patch.
Qualitative and quantitative composition
Neupro 4 mg/24 h transdermal patch: Each patch releases 4 mg of rotigotine per 24 hours. Each patch of 20 cm² contains 9.0 mg of rotigotine. Neupro 6 mg/24 h transdermal patch: Each patch releases 6 mg ...
Pharmaceutical form
Transdermal patch. Thin, matrix-type, square-shaped with rounded edges, consisting of three layers. Neupro 4 mg/24 h transdermal patch: The outside of the backing layer is tan-coloured and imprinted with ...
Therapeutic indications
Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinsons disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course ...
Posology and method of administration
Posology The dose recommendations made are in nominal dose. Dosing in patients with early-stage Parkinsons disease A single daily dose should be initiated at 2 mg/24 h and then increased in weekly increments ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Magnetic resonance imaging or cardioversion (see section 4.4).
Special warnings and precautions for use
If a Parkinsons disease patient is insufficiently controlled while on treatment with rotigotine switching to another dopamine agonist might provide additional benefit (see section 5.1) Magnetic resonance ...
Interaction with other medicinal products and other forms of interaction
Because rotigotine is a dopamine agonist, it is assumed that dopamine antagonists, such as neuroleptics (e.g. phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness ...
Fertility, pregnancy and lactation
Women of childbearing potential, contraception in females Women of childbearing potential should use effective contraception to prevent pregnancy during treatment with rotigotine. Pregnancy There are no ...
Effects on ability to drive and use machines
Rotigotine may have major influence on the ability to drive and use machines. Patients being treated with rotigotine and presenting with somnolence and/or sudden sleep episodes must be informed not to ...
Undesirable effects
Summary of the safety profile Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 1,307 Neuproand 607 placebo-treated patients, 72.5% of the patients on Neupro and ...
Overdose
Symptoms The most likely adverse reactions would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hypotension, involuntary movements, hallucinations, confusion, ...
Pharmacodynamic properties
Pharmacotherapeutic group: Anti-parkinson drugs, dopamine agonists ATC code: N04BC09 Rotigotine is a non-ergolinic dopamine agonist for the treatment of signs and symptoms of Parkinsons disease and Restless ...
Pharmacokinetic properties
Absorption Following application, rotigotine is continuously released from the transdermal patch and absorbed through the skin. Steady-state concentrations are reached after one to two days of patch application ...
Preclinical safety data
In repeated dose and long-term toxicity studies, the major effects were associated with the dopamine agonist related pharmacodynamic effects and the consequent decrease of prolactin secretion. After a ...
List of excipients
Backing layer: Polyester film, siliconized, aluminized, colour coated with a pigment (titanium dioxide (E171), pigment yellow 95, pigment red 166) layer and imprinted (pigment red 144, pigment yellow 95, ...
Incompatibilities
Not applicable.
Shelf life
Shelf life: 30 months.
Special precautions for storage
Do not store above 30°C.
Nature and contents of container
Peel off sachet in a plastic box: One side is composed of an ethylene copolymer (innermost layer), an aluminium foil, low density polyethylene film and paper; the other side is composed of polyethylene ...
Special precautions for disposal and other handling
After use the patch still contains active substance. After removal, the used patch should be folded in half, adhesive side inwards so that the matrix layer is not exposed, placed in the original sachet ...
Marketing authorization holder
UCB Pharma S.A., Allée de la Recherche 60, B-1070, Bruxelles, Belgium
Marketing authorization number(s)
Neupro 4 mg/24 h transdermal patch: EU/1/05/331/004 EU/1/05/331/005 EU/1/05/331/021 EU/1/05/331/024 EU/1/05/331/059 Neupro 6 mg/24 h transdermal patch: EU/1/05/331/007 EU/1/05/331/008 EU/1/05/331/027 ...
Date of first authorization / renewal of the authorization
Date of first authorisation: 15 February 2006 Date of latest renewal: 22 January 2016
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
